Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Classical Hodgkin Lymphoma
Conditions
Classical Hodgkin Lymphoma
Trial Timeline
Jul 26, 2022 → Oct 3, 2027
NCT ID
NCT05404945About Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin
Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin is a phase 2 stage product being developed by Merck for Classical Hodgkin Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05404945. Target conditions include Classical Hodgkin Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05404945 | Phase 2 | Recruiting |
Competing Products
11 competing products in Classical Hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Camrelizumab + Investigator's choice of Chemotherapy | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Sabestomig (AZD7789) | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone | Merck | Phase 2 | 52 |
| Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate | Merck | Phase 2 | 52 |
| Carboplatin + Etoposide + Ifosfamide + Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab (+) Berahyaluronidase alfa | Merck | Phase 2 | 52 |
| Panobinostat | Novartis | Phase 2 | 52 |
| PD1 | Innovent Biologics | Phase 2 | 51 |
| Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine | Bristol Myers Squibb | Phase 1 | 32 |
| Tislelizumab + Salvage Chemotherapy | BeOne Medicines | Phase 3 | 74 |
| GEN3017 | Genmab | Phase 1/2 | 38 |